Olszewska Wieslawa, Openshaw Peter
National Heart and Lung Institute, Centre for Respiratory Infection, Imperial College London, St Mary's Campus, Norfolk Place, Paddington, W21PG London, UK.
Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. doi: 10.1517/14728210902946399.
Although respiratory syncytial virus (RSV) was discovered > 40 years ago, treatment remains largely supportive. There are no safe and effective vaccines or specific treatments other than prophylaxis with passive antibody therapy (palivizumab). However, there are good reasons to think that the scene may soon change. As the pace of development of anti-viral drugs accelerates and optimism over vaccines increases, novel therapies are set to make a major impact in the management of this very common infection. The use and effect of such interventions are not easy to anticipate, but could ultimately include the interruption of RSV's transmission resulting in profound changes to the impact of RSV on human health.
尽管呼吸道合胞病毒（RSV）早在40多年前就已被发现，但治疗方法仍主要以支持性治疗为主。除了通过被动抗体疗法（帕利珠单抗）进行预防外，尚无安全有效的疫苗或特效治疗方法。然而，有充分理由认为这种情况可能很快会改变。随着抗病毒药物研发速度的加快以及对疫苗的乐观情绪增加，新型疗法必将对这种非常常见的感染的治疗产生重大影响。此类干预措施的使用和效果难以预测，但最终可能包括阻断RSV的传播，从而深刻改变RSV对人类健康的影响。
